29 March 2019 - - US-based antibiotics developer Oragenics, Inc. (NYSE American: OGEN) has initiated a collaboration with Florida International University to create computational models of the company's lantibiotic compounds interacting with bacterial membranes and Lipid II, the target of Oragenics' compounds with the ultimate goal of expanding the lantibiotic pipeline, the company said.

The collaboration will develop and refine new computational models for studying lantibiotics as they interact with both Lipid II, the membrane or their host, and each other.

Oragenics then anticipates using this new model toward the development of new compounds that address life-threatening infections.

Oragenics is focused developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis.

The company has established two exclusive worldwide channel collaborations with Intrexon Corp. and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.